Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that are targetable by adoptive T‐cell therapy in metastatic diseases. To expand mutant KRAS‐specific immunotherapies, it is critical to identify additional HLA‐I allotypes that can present KRAS neoantigens and their cognate T‐cell receptors (TCR). Here, we identified a murine TCR specific to a KRAS‐G12V neoantigen (7VVVGAVGVGK16) using a vaccination approach with transgenic mice expressing HLA‐A*03:01 (HLA‐A3). This TCR demonstrated exquisite specificity for mutant G12V and not WT KRAS peptides. To investigate the molecular basis for neoantigen recognition by this TCR, we determined its structure in complex with HLA‐A3(G12V). G12V‐TCR CDR3β and CDR1β formed a hydrophobic pocket to interact with p6 Val of the G12V but not the WT KRAS peptide. To improve the tumor sensitivity of this TCR, we designed rational substitutions to improve TCR:HLA‐A3 contacts. Two substitutions exhibited modest improvements in TCR binding avidity to HLA‐A3 (G12V) but did not sufficiently improve T‐cell sensitivity for further clinical development. Our study provides mechanistic insight into how TCRs detect neoantigens and reveals the challenges in targeting KRAS‐G12V mutations.

Original publication

DOI

10.1002/eji.202451079

Type

Journal article

Journal

European Journal of Immunology

Publisher

Wiley

Publication Date

18/07/2024

Keywords

T cell receptor, KRAS‐G12V, Neoantigen, Immunotherapy, HLA‐A*03:01